Fortress Biotech (FBIO) Stock Statistics & Valuation Metrics

Fortress Biotech has a market cap or net worth of $71.81M. The enterprise value is $69.95M.

Fortress Biotech has 32,202,564 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fortress Biotech’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is -49.97%.

The current PE Ratio of Fortress Biotech is ―. Fortress Biotech’s PEG ratio is -0.15.

In the last 12 months, Fortress Biotech had revenue of 63.26M and earned 6.82M in profits. Earnings per share was -0.07.

In the last 12 months, operating cash flow was -65.78M and capital expenditures 0.00, giving a free cash flow of -65.78M billion.

Fortress Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Fortress Biotech upcoming earnings date is May 18, 2026, TBA (Confirmed).

Fortress Biotech as a current ratio of 2.49, with Debt / Equity ratio of 148.98%

In the past 12 months, Fortress Biotech has paid -620.00K in taxes.

Fortress Biotech EV to EBITDA ratio is -4.81, with an EV/FCF ratio of -1.48.

Fortress Biotech has $79.38M in cash and marketable securities with $74.30M in debt, giving a net cash position of $5.08M billion.

Gross margin is 66.94%, with operating margin of -111.00%, and net profit margin of 10.77%.

The average price target for Fortress Biotech is $10.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy